US Medicare Pricing Policies Could Drive Global Costs and Hinder Access Worldwide
A new modelling study suggests that US Medicare “Most-Favored-Nation” policies on drug prices would cut Medicare spending on brand name drugs, but potentially incentivize companies to increase prices or delay new drug launches elsewhere. Efforts to control the cost of government spending on drugs culminated in a “Most-Favored-Nation” (MFN) policy–a Trump administration initiative which ties […]
We haven't written up this one. Health Policy Watch has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- US Medicare Pricing Policies Could Drive Global Costs and Hinder Access Worldwide healthpolicy-watch.news
